Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954794 | 0.84 | CHRNB2 (0.51) | ADRA1AADRA1D | |
| SCHEMBL6965650 | 0.84 | SLC6A2 (0.40) | ADRA1A | |
| SCHEMBL6968121 | 0.83 | IDO1 (0.35) | ADRA1A | |
| SCHEMBL6961813 | 0.81 | ADRA1A (0.41) | ADRA1AHRH4HRH3ADRA1D | |
| SCHEMBL6962280 | 0.80 | DRD2 (0.46) | ADRA1AHRH4HRH3ADRA1D | |
| Hydrochloric Acid SCHEMBL6963559 | 0.80 | ADRA1A (0.40) | ADRA1AHRH4HRH3ADRA1D | |
| SCHEMBL6963392 | 0.79 | CHRNB2 (0.41) | ADRA1ABACE1ADRA1D | |
| SCHEMBL6962222 | 0.79 | DRD2 (0.43) | NAAAADRA1AHRH3ADRA1D | |
| SCHEMBL6964292 | 0.78 | ADRA1A (0.41) | ADRA1AADRA1D | |
| SCHEMBL6967721 | 0.78 | DRD2 (0.42) | NAAAADRA1AHRH3ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610721-B2 | Imidazo heterocyclic compounds | NOVO NORDISK A/S (DK) | 2003-08-26 | — | — | US | disclosed |
| EP-1268483-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-20010049385-A1 | Imidazo heterocyclic compounds | HIGH POINT PHARMACEUTICALS, LLC | 2001-12-06 | — | — | US | disclosed |
| WO-2001068651-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049385-A1 | Imidazo heterocyclic compounds | HRH4, HRH3, HRH2 | NAAA 534/4885ADRA1A 212/4885BACE1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.